Phase 3 trials show oral semaglutide failed to slow early Alzheimer’s progression, potentially limiting its expansion beyond metabolic care. The outcome affects Novo Nordisk and competitors, reinforcing focus on obesity and diabetes markets in Mexico, where demand and healthcare investment remain high.

Oral semaglutide did not slow cognitive decline in early-stage Alzheimer’s disease, according to results from two large Phase 3 trials. The studies found no significant difference between the drug and placebo on clinical progression. The findings challenge earlier evidence suggesting GLP-1 therapies could reduce dementia risk.

Investigators published a paper in The Lancet reporting that semaglutide “was not efficacious in slowing clinical progression in participants with early Alzheimer’s disease,” underscoring the gap between biological signals and measurable clinical outcomes in neurodegenerative research. The evoke and evoke+ trials evaluated oral semaglutide, developed by Novo Nordisk, as a potential treatment targeting metabolic and inflammatory pathways implicated in Alzheimer’s disease.

The randomized, double-blind, placebo-controlled Phase 3 studies were conducted across 566 sites in 40 countries. A total of 3,808 participants aged 55 to 85 with biomarker-confirmed Alzheimer’s disease were enrolled, all presenting with mild cognitive impairment or mild dementia.

Participants were assigned to receive once-daily semaglutide, up to 14mg, or placebo for up to 156 weeks. The primary endpoint was change in the Clinical Dementia Rating — Sum of Boxes (CDR-SB) score at 104 weeks.

Results showed no statistically significant difference between the groups. In the evoke trial, CDR-SB scores increased by 2.3 points in both the semaglutide and placebo arms. In evoke+, scores rose by 2.2 points in the treatment group and 2.1 points in the placebo group. The findings indicate that semaglutide did not slow cognitive or functional decline in early-stage Alzheimer’s disease.

Biomarker Effects Highlight Limits of Mechanism

Despite the lack of clinical efficacy, semaglutide showed measurable effects on several biomarkers associated with Alzheimer’s pathology. In a cerebrospinal fluid substudy, the drug reduced levels of phosphorylated tau proteins and markers of neuroinflammation and neurodegeneration. It also lowered systemic inflammatory markers, including C-reactive protein.

These findings align with prior hypotheses that GLP-1 receptor agonists may influence pathways linked to neurodegeneration, including inflammation, vascular dysfunction, and metabolic regulation. However, the absence of clinical benefit suggests that these biological effects are insufficient to alter disease progression on their own.

Safety outcomes were consistent with semaglutide’s established profile in metabolic indications. Adverse events were reported in more than 90% of participants receiving the drug, compared with about 85% in the placebo group. Gastrointestinal symptoms were the most common. Five deaths were considered treatment-related by investigators, including one in the semaglutide group and four in the placebo arm.

Additional analyses showed no delay in progression from mild cognitive impairment to dementia over the course of the trials, reinforcing the primary findings.

Broader Evidence Expands Alzheimer’s Research Focus

The results come as Alzheimer’s research continues to expand beyond traditional amyloid-targeting approaches, incorporating biomarkers, clinical events, and lifestyle factors into disease models.

Recent studies have identified blood-based biomarkers such as p-tau217 and GFAP as strong predictors of disease progression. Elevated levels of these markers have been associated with accelerated declines in cognition and daily functioning, supporting their use in early detection and patient stratification.

Acute clinical events also play a role. Episodes of delirium have been linked to faster disease progression, with measurable impacts on cognitive decline that can exceed those observed in some therapeutic trials. These findings suggest that managing acute neurological complications may be critical to improving outcomes.

Lifestyle factors, particularly sleep, are also gaining attention. Longitudinal research indicates that chronic insomnia can increase dementia risk and contribute to structural brain changes associated with neurodegeneration. Behavioral interventions are increasingly viewed as complementary strategies in disease management.

Globally, an estimated 55 million people live with dementia, with projections reaching 78 million by 2030. In Mexico, approximately 7.8% of adults over age 60 are affected, with prevalence expected to rise as the population ages.

GLP-1 Market Advances Despite Setback

The outcome of the semaglutide trials contrasts with continued growth in the GLP-1 receptor agonist market for metabolic diseases.

Eli Lilly and Company recently reported that its investigational oral GLP-1 candidate outperformed semaglutide in a head-to-head Phase 3 trial for type 2 diabetes. The study showed greater reductions in blood glucose and body weight over 52 weeks, reinforcing competition in the oral GLP-1 segment.

At the same time, regulatory momentum continues for semaglutide in obesity and diabetes care, including oral formulations that expand access beyond injectable therapies. Global health authorities have endorsed GLP-1 drugs for long-term obesity management, though access remains limited by cost and healthcare system constraints.

In markets such as Mexico, where obesity and type 2 diabetes prevalence remain high, pharmaceutical companies are increasing investment in clinical research and access strategies. These dynamics underscore the continued relevance of GLP-1 therapies in cardiometabolic care.

For stakeholders, the evoke+ results define a clearer boundary for semaglutide’s role. While the drug remains central in metabolic treatment, its inability to demonstrate efficacy in Alzheimer’s disease may redirect research toward combination approaches and alternative targets.

As more than 70% of the Alzheimer’s pipeline now focuses on non-amyloid mechanisms, the findings reinforce the complexity of the disease and the need for multidimensional strategies to achieve meaningful clinical outcomes.